Actelion Pharmaceuticals Ltd and Actelion Ltd is a Swiss pharmaceutical company headquartered in Allschwil, Basel-Landschaft. The company specializes in the development and distribution endothelbezogener agents.
The company employed a total of 2,396 employees in January 2013, 370 of them in the research, development and 585 in 1026 in sales and marketing. 2013 Actelion generated sales of 1.784 billion Swiss francs.
Actelion was founded in December 1997. Founder and CEO is the cardiologist Jean -Paul Clozel. After Actelion was listed on the Swiss Stock Exchange SWX Swiss Exchange since 2000 in the Swiss Leader Index the thirty largest and most liquid Swiss stocks, the company was incorporated September 22, 2008, in the Swiss Market Index.
The company has offices in over 20 countries (Australia, Belgium, Brazil, Germany, France, Greece, Israel, Italy, Japan, Canada, Korea, the Netherlands, Austria, Portugal, Sweden, Switzerland, Spain, Czech Republic, Turkey, United States, United Kingdom). The German office is located in Freiburg im Breisgau, the Austrian in Vienna.
Developed by Actelion and already on the market are the orphan drug:
- Tracleer ® ( bosentan): an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension
- Zavesca ® ( miglustat): an inhibitor of the enzyme glucosylceramide synthase ( glucosylceramide is a cerebroside derivative) to treat mild to moderate cases of Gaucher disease type I
- Opsumit ® ( Macitentan ): an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension
Among other things, Actelion markets in the U.S., the drug developed by Schering AG
- Ventavis ® ( iloprost): a prostacyclin analogue for inhalation therapy of primary pulmonary hypertension ( NYHA III)